Patents by Inventor Joel SCHICK

Joel SCHICK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
    Patent number: 10647687
    Abstract: The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 12, 2020
    Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
    Patent number: 10280179
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterized by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: May 7, 2019
    Assignee: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH
    Publication number: 20180362475
    Abstract: The present invention relates to spiropyrazine compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Application
    Filed: November 10, 2015
    Publication date: December 20, 2018
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH
    Publication number: 20180065982
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Application
    Filed: September 18, 2017
    Publication date: March 8, 2018
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
    Patent number: 9802956
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: October 31, 2017
    Assignee: Helmholtz Zentrum Munchen-Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn
  • SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH
    Publication number: 20160222025
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Application
    Filed: July 15, 2014
    Publication date: August 4, 2016
    Inventors: Marcus CONRAD, Joel SCHICK, Bettina PRONETH, Peter SENNHENN
  • Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
    Patent number: RE48992
    Abstract: The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: March 29, 2022
    Assignee: Helmholtz Zentrum München-Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventors: Marcus Conrad, Joel Schick, Bettina Proneth, Peter Sennhenn